| |
mGFR (mL/min/1.73 m
2
)
|
eGFR (Cockcroft-Gault) (mL/min/1.73 m
2
)
|
Serum creatinine (mg/dL)
|
|---|
| |
Tofacitinib → placebo group
|
Placebo → placebo group
|
Tofacitinib → placebo group
|
Placebo → placebo group
|
Tofacitinib → placebo group
|
Placebo → placebo group
|
|---|
|
Baseline
|
|
Number
|
97
|
51
|
97
|
51
|
97
|
51
|
|
Mean (SD)
|
88.98 (18.79)
|
89.67 (21.33)
|
104.19 (28.42)
|
111.30 (26.91)
|
0.77 (0.15)
|
0.76 (0.17)
|
|
Median (Q1, Q3)
|
87.98 (75.76, 99.98)
|
86.99 (75.17, 98.20)
|
97.22 (82.43, 125.57)
|
107.22 (91.47, 134.89)
|
0.76 (0.67, 0.85)
|
0.75 (0.64, 0.84)
|
|
Change at end of period 1 from baseline
|
|
Number
|
91
|
46
|
92
|
46
|
92
|
46
|
|
Mean (SD)
|
−6.73 (16.44)
|
−0.50 (17.34)
|
−3.59 (10.31)
|
1.28 (11.48)
|
0.03 (0.07)
|
−0.00 (0.07)
|
|
Median (Q1, Q3)
|
−6.46 (−11.85, 2.14)
|
0.82 (−5.48, 6.79)
|
−3.36 (−9.18, 2.86)
|
2.30 (−5.71, 6.14)
|
0.02 (−0.02, 0.08)
|
−0.01 (−0.05, 0.04)
|
|
Change at end of period 2 from baseline
|
|
Number
|
86
|
45
|
87
|
44
|
87
|
44
|
|
Mean (SD)
|
−3.02 (17.55)
|
−5.96 (20.66)
|
0.03 (10.15)
|
0.48 (9.54)
|
0.00 (0.07)
|
−0.00 (0.05)
|
|
Median (Q1, Q3)
|
−3.41 (−8.55, 3.65)
|
−3.88 (−9.13, 7.58)
|
−0.32 (−6.05, 5.74)
|
0.18 (−3.81, 4.28)
|
0.00 (−0.05, 0.05)
|
0.00 (−0.03, 0.03)
|
|
Change at end of period 2 from end of period 1
|
|
Number
|
86
|
45
|
87
|
44
|
87
|
44
|
|
Mean (SD)
|
2.92 (19.02)
|
−5.41 (16.65)
|
3.71 (11.95)
|
−0.97 (10.06)
|
−0.03 (0.08)
|
0.00 (0.07)
|
|
Median (Q1, Q3)
|
1.68 (−3.60, 8.62)
|
−3.25 (−12.24, 2.29)
|
2.94 (−4.45, 10.31)
|
−2.07 (−7.29, 6.09)
|
−0.02 (−0.07, 0.03)
|
0.01 (−0.04, 0.05)
|
- eGFR, estimated glomerular filtration rate; mGFR, measured glomerular filtration rate; Q1, 25th percentile; Q3, 75th percentile; SD, standard deviation.
